文献速递肝肾功能剂量调整特殊人群用药治疗药物监测与药物基因组学

基因型指导给药改善肾移植后CYP3A5正常代谢者治疗谷浓度达标

Genotype-Guided Dosing Improves Attainment of Therapeutic Troughs in CYP3A5 Normal Metabolizers After Kidney Transplantation.
PubMed 文献 · Am J Health Syst Pharm · 2026-10-12

基因型指导组中CYP3A5正常代谢者达到治疗谷浓度(≥8 ng/mL)的时间显著缩短(中位13天 vs 25天,P=0.007),且未增加超治疗浓度或不良临床结局。

要点

  • CYP3A5正常代谢者接受基因型指导缓释他克莫司给药可更快达到治疗谷浓度。
  • 基因型指导组术后第3天谷浓度更高且更接近治疗目标。
  • 基因型指导给药未增加超治疗浓度或不良临床结局风险。

核心结论

  • 基因型指导的缓释他克莫司给药可改善CYP3A5正常代谢者的早期他克莫司浓度并显著缩短治疗谷浓度达标时间。

主要发现

  • 基因型指导组中CYP3A5正常代谢者达到治疗谷浓度≥8 ng/mL的时间显著优于常规组(中位13天 vs 25天,P=0.007),但整体队列中无显著差异。
  • 基因型指导组中正常和中间代谢者术后第3天他克莫司谷浓度显著更高且更接近治疗目标。
  • 基因型指导给药未增加超治疗他克莫司浓度发生率或不良临床结局。

关键数值与推荐

  • 常规固定剂量为缓释他克莫司4 mg每日一次;基因型指导剂量为正常代谢者8 mg每日一次、中间代谢者6 mg每日一次。
  • 主要结局为达到治疗谷浓度(≥8 ng/mL)的时间。

临床怎么用

  • 可考虑在肾移植前进行CYP3A5基因分型,对正常代谢者采用基因型指导的缓释他克莫司起始剂量以优化早期浓度达标。

局限性

  • 本研究为回顾性单中心队列研究,样本量有限,结论需更大规模前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: CYP3A5 expressors experience delayed therapeutic tacrolimus concentrations after kidney transplantation, thus, requiring higher tacrolimus doses. Although genotype-guided dosing has demonstrated benefit with immediate-release tacrolimus, data evaluating tacrolimus extended-release (XR) formulations is limited. METHODS: This retrospective, single-center cohort study included adult kidney transplant recipients with CYP3A5 normal or intermediate metabolizer phenotypes initiated on tacrolimus XR between November 2020 and August 2025. Patients received either conventional fixed-dose tacrolimus XR 4 mg daily or genotype-guided dosing (8 mg daily for normal metabolizers and 6 mg daily for intermediate metabolizers). The primary outcome was time to therapeutic tacrolimus trough concentration (≥8 ng/mL). Secondary outcomes included total dose adjustments, rate of supratherapeutic troughs, intrapatient variability, rejection rate, and renal function. RESULTS: Eighty-one patients met inclusion criteria, including 43 patients in the conventional dosing group and 38 patients in the genotype-guided group. Genotype-guided dosing significantly improved time to therapeutic troughs ≥8 in the normal metabolizers (median 13 vs 25 days; P=0.007), but not in the overall cohort. Both normal and intermediate metabolizers in the genotype-guided group demonstrated significantly higher tacrolimus trough concentrations that were closer to the therapeutic target on post-operative day 3. Genotype-guided dosing was not associated with an increased incidence of supratherapeutic tacrolimus concentrations or adverse clinical outcomes. CONCLUSION: Genotype-guided tacrolimus XR dosing improved early tacrolimus concentrations and significantly shortened time to therapeutic trough attainment among CYP3A5 normal metabolizers. These findings support the use of pre-transplant CYP3A5 genotyping to optimize tacrolimus XR dosing in normal metabolizers.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Nguyen L, Przybylski A, Joyce C, et al. Genotype-Guided Dosing Improves Attainment of Therapeutic Troughs in CYP3A5 Normal Metabolizers After Kidney Transplantation. Am J Health Syst Pharm. 2026. PMID: 42862104. doi:10.1093/ajhp/zxag330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。